<DOC>
	<DOCNO>NCT00231309</DOCNO>
	<brief_summary>The major purpose study evaluate curative potential white cell growth hormone ( G-CSF ) -stimulated bone marrow cell allogeneic bone marrow transplant . Patients cancer blood disease , poor potential cure standard treatment , able participate study . Donors receive white cell growth hormone ( G-CSF ) shot ( injection ) arm day three day donate bone marrow cell . Total body irradiation and/or chemotherapy give first prepare patient 's body infusion new bone marrow cell donor . Two medicine ( cyclosporine methotrexate ) use prevent new bone marrow cell ( graft ) attack patient 's body ( host ) ( graft-versus-host disease ; GVHD ) . Certain safety checkpoint build study unwanted/unexpected event occur . If outcomes appear well could expect , provide bridge extend current approach innovative therapy .</brief_summary>
	<brief_title>Granulocyte Colony Stimulating Factor ( G-CSF ) Bone Marrow Transplant ( BMT )</brief_title>
	<detailed_description>This study single-arm , non-randomized trial . Patients meet criterion study enter sequentially completion closure study . Early stopping rule employ ascertain whether unacceptable rate toxicity ( non-engraftment , and/or acute GvHD ) occur . Patients prepare transplant administration one follow condition regimen base his/her primary disease : 5.1 Total body irradiation 1200 rads 6 fractionated dos high dose chemotherapy , include etoposide cyclophosphamide . 5.2 High dose chemotherapy busulfan cyclophosphamide . 5.2.1 Patients candidate TBI receive chemotherapy-based conditioning regimen . 5.3 Post transplant immunosuppression prophylaxis acute GVHD include cyclosporine methotrexate . 5.4 Donor receive 3 daily G-CSF injection ( start day -3 ) prior marrow harvest . The injection may initiate donor 's primary physician prior donor 's arrival , BMT service Children 's Healthcare Atlanta . 5.5 Patients receive daily G-CSF injection ( 5 mcg/kg ) start day+5 post transplant .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients hematologic malignancy nonmalignancies candidate match sibling donor allogeneic bone marrow transplantation eligible study . Patients 55 year age . Patients life expectancy least 12 week performance status least 2 Zubrod 70 % Karnofsky status prior transplantation . Patients acceptable candidate marrow transplantation base preBMT evaluation . Patients available histocompatible sibling medically approve marrow donor . Patients sign inform consent protocol approve Institutional Review Board Emory University/Children 's Healthcare Atlanta . Donors must 5 year age old , complete routine donor evaluation sign ( parent legal guardian ) inform consent protocol approve Institutional Review Board Emory University/Children 's Healthcare Atlanta . Patients exclude base sex , racial , ethnic background . Patients exclude demonstrate significant functional deficit major organ , would obviously interfere successful outcome follow bone marrow transplant utilize follow guideline : Evidence active , deep seat , lifethreatening infection know effective therapy ( e.g . certain fungal specie , HIV , etc. ) . Patients hemoglobinopathy ( e.g . sickle cell disease thalassemia ) eligible protocol . However , filgrastim mobilization , large volume apheresis , processing , cryopreservation appear safe donor sickle cell trait . Patients great two leukemic episode , active central nervous system ( CNS ) and/or leukemic disease blast crisis chronic myelogenous leukemia ( CML ) patient . Patients exclude woman childbearing potential currently pregnant ( betahCG+ ) practice adequate contraception . Patients previous stem cell transplant exclude . Donors exclude sensitive E. coliderived protein .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>G-CSF</keyword>
	<keyword>Bone Marrow</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Non-malignancies</keyword>
	<keyword>Matched sibling donor</keyword>
	<keyword>Allogeneic BMT</keyword>
</DOC>